A change in the timing for starting systemic therapies for hepatocellular carcinoma: the comparison of sorafenib and lenvatinib as the first-line treatment.
Acta Gastroenterol Belg
; 84(1): 65-72, 2021.
Article
in En
| MEDLINE
| ID: mdl-33639695
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Liver Neoplasms
/
Antineoplastic Agents
Type of study:
Observational_studies
Limits:
Aged
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Acta Gastroenterol Belg
Year:
2021
Document type:
Article
Country of publication:
Belgium